Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling

Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling

Abstract Background One of the major challenges in managing invasive breast cancer (BC) is the lack of reliable biomarkers to track response. Circulating tumor DNA (ctDNA) from liquid biopsy, as a candidate biomarker, provides a valuable assessment of BC patients. In this retrospective study, we eva...

Full description

Bibliographic Details
Main Authors: Zhanhong Chen, Tian Sun, Ziyan Yang, Yabing Zheng, Ruoying Yu, Xue Wu, Junrong Yan, Yang W Shao, Xiying Shao, Wenming Cao, Xiaojia Wang
Format: Article
Language:English
Published: Wiley 2020-02-01
Series:Molecular Genetics & Genomic Medicine
Subjects:
breast cancer
chemotherapy
ctDNA
drug resistance
ERBB2
trastuzumab
Online Access:https://doi.org/10.1002/mgg3.1079

Internet

https://doi.org/10.1002/mgg3.1079

Similar Items